Can You Lower the Dose and Keep the Weight Off?

Once the weight is off, what is the smallest amount of drug that holds it? A 2026 randomized trial finally tested that, comparing people who stayed on their maximum tolerated tirzepatide dose against people dropped to 5 mg and people moved to placebo. The weight numbers are the ones that will get quoted. The number that matters more is how many in each group needed rescue therapy: 8%, 25% and 67%.^[1]

What was compared

Participants who had already lost weight on tirzepatide were randomized to continue at their maximum tolerated dose, to step down to 5 mg, or to switch to placebo, and followed to week 112. They began with a mean body weight of 113.8 kg and a mean BMI of 40.1.^[1]

So a lower dose does hold a substantial part of the loss — and it holds meaningfully less than staying put. The authors describe reducing to 5 mg as a valuable alternative to discontinuation, which is a careful phrase and the right one: better than stopping, worse than continuing.^[1]

The column nobody will quote

Rescue therapy is what happens when a participant’s clinical situation deteriorates enough that the trial protocol allows intervention. It converts an abstract percentage into an event: something had to be done.

Two thirds of the placebo group needed rescue therapy. That is what stopping looks like as a clinical event rather than a number on a chart.

It also reframes the dose-reduction question. Stepping down to 5 mg tripled the rescue rate against staying at the full dose — 25% against 8% — while still being far better than the 67% on placebo. If you are weighing a lower dose to save money or reduce side effects, that tripling is the cost, and it is invisible in the weight figures.

What this means for microdosing

We wrote recently that no randomized trial of microdosing exists, and that remains true: 5 mg of tirzepatide is a labeled dose, not a microdose, and this trial does not test the sub-labeled dosing that 62 sellers in our register offer.

But it is the closest randomized evidence to the underlying idea, and it points both ways at once. Less drug did hold much of the loss, which is the strongest support the microdosing premise has ever had. And less drug did measurably worse on the outcome that matters clinically, which is the part the marketing will leave out.

How to use this

• Long-term treatment is the design assumption now. The trial’s own framing is that ongoing therapy is usually necessary to maintain the reduction — which makes affordability a clinical question, not just a financial one.
• A dose reduction is a legitimate clinical option, and it is one to make with a prescriber who can watch what happens rather than by choosing a cheaper subscription tier.
• Response varies. The authors say so explicitly; group means do not tell you which group you are in.
• Side effects were mostly during escalation, and mostly mild to moderate gastrointestinal — relevant if tolerability is what is driving you toward a lower dose.